Life Sciences

The challenges facing the life sciences industry are increasing — long product development timelines, increased regulatory hurdles, pricing pressure, industry consolidation, access to capital…the list goes on. To build value and sustain the life of your enterprise, you need life sciences counsel with the industry knowledge and legal experience to help you execute sound business strategies, minimize risks, and take advantage of opportunities.

Since the birth of the life sciences industry in the 1970s, we have provided companies with the experience, resources, and insights to help them meet their goals. Today, we work with clients globally, including companies of every size — from start-ups with little more than an idea to large public companies with products on the market, venture capital firms and investment banks, and research organizations and institutions.

Quick Facts


  • 30+ years in the life sciences industry
  • Integrated intellectual property and corporate practice
  • Specialize in IPOs for companies developing ground-breaking technologies
  • National Tier 1 ranking for Biotechnology Law – U.S. News & World Report and Best Lawyers "Best Law Firms" (2011-2014)
  • Ranked as "Law Firm of the Year (Biotechnology) – North America" by M&A Today Global Awards (2014)
  • "Licensing and Collaborations Firm of the Year" by LMG Life Sciences (2013)

Areas of Focus

Compliance and regulation

  • Compliance planning
  • FDA regulatory
  • Health care fraud and abuse
  • Reimbursement

Corporate


Intellectual property


Sort by: Name  Title  Office

Lisa Adams

Lisa Adams

Member

Boston 617.348.3054
Priya K. Agrawal

Priya K. Agrawal

Associate

New York 212.692.6708
New York 212.692.6866
Boston 617.348.1824
Shovon Ashraf, PhD

Shovon Ashraf, PhD

Associate

Boston 617.348.4964
Avisheh Avini

Avisheh Avini

Of Counsel

New York 212.692.6200
Christine M. Baker

Christine M. Baker

Of Counsel

New York 212.692.6236
David Barmak

David Barmak

Member

Washington, DC 202.585.3507
John A. Bauer

John A. Bauer

Member

New York 212.692.6795
Stamford 203.658.1700
Eoin P. Beirne

Eoin P. Beirne

Associate

Boston 617.348.1707
Boston 617.348.1784
Emma Bevan

Emma Bevan

Member

London, UK +44.20.7776.7379
Boston 617.348.4472
Scott Biel

Scott Biel

Member

San Diego 858.314.1555
Los Angeles 310.586.3200
San Francisco 415.432.6000
New York 212.692.6869
New York 212.692.6784
Boston 617.348.3073
Boston 617.348.1614
Boston 617.348.1613
Boston 617.348.3097
Boston 617.348.1705
Jessica W. Catlow

Jessica W. Catlow

Associate

New York 212.692.6843
Boston 617.348.1840
Boston 617.348.1742
Barbara Chin

Barbara Chin

Associate

Boston 617.348.4405
Victoria Clarke

Victoria Clarke

Associate

London, UK +44.20.7776.7372
William L. Coffman

William L. Coffman

Of Counsel

Boston 617.348.1890
Boston 617.348.4468
Stephen P. Cole

Stephen P. Cole

Associate

Boston 617.348.1605
Hannah C. Coman

Hannah C. Coman

Associate

Boston 617.348.1703
John P. Condon

John P. Condon

Associate

Boston 617.348.4453
James Conley

James Conley

Member

San Diego 858.314.1514
Boston 617.348.1676
Washington, DC 202.661.8787
Julian Crump

Julian Crump

Member

London, UK +44.20.7776.7302
New York 212.692.6217
Boston 617.348.1670
New York 212.692.6703
Boston 617.348.1797
Rebecca Diamond

Rebecca Diamond

Associate

Boston 617.348.1878
New York 212.692.6853
Brian P. Dunphy

Brian P. Dunphy

Associate

Boston 617.348.1810
Matthew D. Durell

Matthew D. Durell

Associate

Boston 617.348.1615
New York 212.692.6230
Eric J. Eastham

Eric J. Eastham

Associate

San Diego 858.314.1877
Boston 617.348.1635
Boston 617.348.3003
Isobel Finnie

Isobel Finnie

Member

London, UK +44.20.7776.7318
Boston 617.348.4474
London, UK +44.20.7776.7330
London, UK 011.44.790.881.9030
Boston 617.348.3051
Boston 617.348.4443
Boston 617.348.1834
Kristin A. Gerber

Kristin A. Gerber

Associate

Boston 617.348.3043
Merav Gershtenman

Merav Gershtenman

Associate

New York 212.692.6806
New York 212.692.6247
John Giust

John Giust

Member

San Diego 858.314.1572
San Diego 858.314.1515
San Francisco 415.432.6000
Arun K. Goel

Arun K. Goel

Associate

San Diego 858.314.1582
Boston 617.348.1623
London, UK +44.20.7776.7351
Boston 617.348.1651
Joseph P. Hammang, PhD

Joseph P. Hammang, PhD

ML Strategies - Senior Vice President, Life Sciences

Washington, DC 202.434.7407
Douglas Hauer

Douglas Hauer

Member

Boston 617.348.3044
Boston 617.348.1654
Kanasha S. Herbert

Kanasha S. Herbert

Associate

Boston 617.348.3015
San Diego 858.314.1518
Boston 617.348.1799
New York 212.692.6830
Sarah T. Hogan

Sarah T. Hogan

Associate

Boston 617.348.1883
Boston 617.348.1813
Boston 617.348.1706
Boston 617.348.4939
London, UK +44.20.7776.7311
Boston 617.348.1715
Boston 617.348.3093
Crystal L. Kellas, PhD

Crystal L. Kellas, PhD

Technology Specialist

Boston 617.348.4973
Boston 617.239.8491
Maryanne Kline

Maryanne Kline

Associate

Boston 617.239.8498
New York 212.692.6768
Boston 617.348.1638
John B. Koss

John B. Koss

Associate

Boston 617.348.1641
Boston 617.348.1674
San Diego 858.314.1535
Los Angeles 310.586.3200
San Francisco 415.432.6000
San Diego 858.314.1525
Wynter N. Lavier

Wynter N. Lavier

Associate

Boston 617.348.4712
Boston 617.348.4780
Boston 617.348.4832
Boston 617.348.3032
Boston 617.348.1682
San Diego 858.314.1509
San Francisco 415.432.6104
Washington, DC 202.434.7452
San Diego 858.314.1519
Warren W. Ma

Warren W. Ma

Associate

San Diego 858.314.1587
Boston 617.348.3058
Boris A. Matvenko

Boris A. Matvenko

Of Counsel

New York 212.692.6858
Boston 617.348.1683
Boston 617.348.4402
New York 212.692.6794
Jessica D. Mendoza

Jessica D. Mendoza

Associate

San Francisco 415.432.6085
Boston 617.348.1694
Linyu L. Mitra, PhD

Linyu L. Mitra, PhD

Technology Specialist

Boston 617.348.3006
Tavis J. Morello

Tavis J. Morello

Associate

Boston 617.348.4464
Boston 617.348.1620
New York 212.692.6774
Maura M. Pelham

Maura M. Pelham

Contract Attorney

Boston 617.348.1851
New York 212.692.6859
New York 212.692.6838
Heike S. Radeke

Heike S. Radeke

Technology Specialist

Boston 617.348.4869
Linda Rockett

Linda Rockett

Member

Boston 617.348.4888
San Diego 858.314.1527
Los Angeles 310.586.3200
San Francisco 415.432.6080
Miles Roeder

Miles Roeder

Associate

Boston 617.348.3017
Jake Romero

Jake Romero

Associate

San Diego 858.314.1584
Stamford 203.388.8464
New York 212.692.6766
John T. Rudy

John T. Rudy

Associate

Boston 617.348.3050
San Diego 858.314.1873
New York 212.692.6804
Boston 617.348.1798
Boston 617.348.1725
Dawn Saunders

Dawn Saunders

Member

San Diego 858.314.1875
Jack C. Schecter

Jack C. Schecter

Of Counsel

Boston 617.348.3083
Natalie K. Schiller, PhD

Natalie K. Schiller, PhD

Senior Patent Agent

San Diego 858.314.1547
Boston 617.348.1764
New York 212.692.6732
Daniel Sellwood

Daniel Sellwood

Technical Assistant

London, UK +44.20.7776.7338
Jessica C. Sergi

Jessica C. Sergi

Associate

Boston 617.348.1766
Bram Shapiro

Bram Shapiro

Member

Boston 617.348.1610
Andrew J. Shin

Andrew J. Shin

ML Strategies - Director, Health Care Policy & Life Sciences

Washington, DC 202.434.7487
Farrah Short

Farrah Short

Associate

Washington, DC 202.585.3518
Boston 617.348.3039
San Diego 858.314.1506
New York 212.692.6704
Sahir Surmeli

Sahir Surmeli

Member

Boston 617.348.3013
Boston 617.348.1820
Tali M. Tuchin

Tali M. Tuchin

Of Counsel

San Diego 858.314.1558
Jonathan Urbon

Jonathan Urbon

Associate

Boston 617.348.1844
Adam M. Veness

Adam M. Veness

Associate

Boston 617.348.4432
Ben L. Wagner

Ben L. Wagner

Associate

San Diego 858.314.1512
Los Angeles 310.586.3200
Christine M. Wahr

Christine M. Wahr

Associate

Boston 617.348.3014
Boston 617.348.1757
Boston 617.348.1869
Boston 617.348.1759
San Diego 858.314.1522
Los Angeles 310.586.3200
Garrett M. Winslow

Garrett M. Winslow

Associate

Boston 617.348.3028
Monique Winters

Monique Winters

Associate

San Diego 858.314.1542
Howard Wisnia

Howard Wisnia

Member

San Diego 858.314.1592
San Francisco 415.432.6101
Dean G. Zioze

Dean G. Zioze

Member

Boston 617.348.4795

Antitrust

  • Served as antitrust counsel for a leading provider of sample and assay technologies, and are currently involved in counseling and representing the company in merger and acquisition activities.

Corporate & Securities: Joint Ventures, Strategic Alliances, Collaborations & Technology Transfer

  • Represented Inhibrx LLC in its June 2012 Option and License Agreement with Celgene Corporation.
  • Represented GreatPoint Energy, Inc. in its March 2012 $400 million Series D financing led by China Wanxiang Holding Co. Ltd.
  • Represented Angiochem, Inc. in its February 2012 collaboration with GlaxoSmithKline (GSK).
  • Represented Intarcia Therapeutics, Inc. in its December 2011 strategic alliance with Quintiles.
  • Represented ArQule, Inc. (NASDAQ: ARQL) in the November 2011 execution of a license agreement with Daiichi Sankyo, Co. Ltd.
  • Represented BeiGene, LLC on the exclusive in-licensing and co-development agreements of October 2011 with Janssen Pharmaceutica NV and CNA Development, LLC, divisions of Johnson & Johnson (NYSE: JNJ).

Corporate & Securities: Mergers & Acquisitions

  • Represented Piramal Healthcare Limited, an India-based drug company, in its acquisition of Decision Resources Group, a Massachusetts-based health care information data provider.
  • Represented Boston Biomedical, Inc. (BBI) in its sale to Dainippon Sumitomo Pharma Co., Ltd. (DSP) for up to $2.63 billion in total, which included $200 million upfront, up to $540 million in development milestone payments, and up to $1.89 billion in sales milestone payments.
  • Represented Caliper Life Sciences, Inc. in its $600 million sale to Perkin Elmer, Inc.
  • Represented Ion Torrent Systems, Inc. in its $725 million sale to Life Technologies Corporation.
  • Represented QIAGEN NV in its $1.6 billion acquisition of Digene Corporation, including antitrust aspects of the transaction.
  • Represented the exclusive financial advisor to Diagnostic Products Corporation in its $1.8 billion acquisition by Siemens Medical Solutions.
  • Represented Vertex Pharmaceuticals, Inc. in its $400 million acquisition of ViroChem Pharma, Inc.
  • Represented China-based BioDuro, LLC in its $77 million acquisition by Pharmaceutical Product Development, Inc.

Corporate & Securities: Securities

  • Served as underwriters’ counsel to Leerink Swann in the $23.7 million underwritten public offering in January 2012 by Chelsea Therapeutics International Ltd. (NASDAQ: CHTP).
  • Represented GI Dynamics, Inc. (ASX: GID) in the filing of its Australian IPO and contemporaneous US private placement, which raised a combined $85 million in September 2011.
  • Served as placement agent counsel to Leerink Swann in the $55 million private placement in September 2011 by Puma Biotechnology.
  • Represented BofA Merrill Lynch and Leerink Swann as underwriters’ counsel in a $65 million shelf offering for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) in June 2011.
  • Represented ImmunoGen Inc., (NASDAQ: IMGN) in its $93.6 million follow-on underwritten public offering in May 2011. Jefferies & Company Inc. acted as the sole book-running manager for the offering and Oppenheimer & Co. Inc., RBC Capital Markets LLC, William Blair & Company LLC, Canaccord Genuity Inc., and Morgan Joseph TriArtisan LLC acted as co-managers for the offering.
  • Represented Rosetta Genomics, Inc. (NASDAQ: ROSG) in its concurrent PIPE / registered direct offering in February 2011. Rodman & Renshaw acted as the exclusive placement agent for both offerings.
  • Represented ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) in its $258 million public offering in December 2011. JPMorgan, Cowen and Company, and Jefferies served as underwriters.

Employment, Labor & Benefits

  • Counseled a public international life sciences company on company-wide and department-wide reorganization, ensuring compliance with state and federal wage / hour laws, the federal WARN Act and state analogs, and state and federal anti-discrimination laws.
  • Counseled a public international life sciences company on employment agreements and compensation packages for senior executives and senior management teams.

Health Law

  • Drafted and negotiated IT vendor agreements necessary to help a late-stage biotech company prepare for commercial operations in anticipation of the launch of its first drug, including cloud services agreements, a master agreement to build and implement an IVRS / IWRS system to support clinical trials, a master agreement to implement and provide an enterprise-wide expense report system, a sales force automation service for the company’s commercial drug team, a data management / storage services agreement, and a master services agreement to implement and provide a data management solution to support various departments.
  • Developed a multistate HIPAA and Red Flags privacy compliance infrastructure for a US-based biosciences company specializing in the development and commercialization of clinically validated molecular diagnostics and anatomic pathology services.

Litigation

  • Obtained over a million-dollar verdict on behalf of AstraZeneca against its former CEO for fraud, conversion, and breach of fiduciary duty. While defeating the CEO’s claims for defamation, we obtained a favorable appellate decision before the Supreme Judicial Court, which has now resulted in an $18 million judgment in favor of AstraZeneca. This has been recognized by former Chief Justice Margaret Marshall as one of her “notable decisions” under the category of free speech.
  • Advised a medical device manufacturer on a federal investigation into potential trade-based money laundering and black market peso transactions by Colombian distributor.
  • Decision by the Massachusetts Supreme Judicial Court to reverse the decision of the trial court resulting in our client, a pharmaceutical company, recovering nearly $7 million in compensation and bonuses from a disloyal former CEO.
  • Defended a dental product manufacturer in a products liability action involving the alleged failure of its products and resulting injuries. Obtained defense verdict after trial on the merits.
  • Developed a comprehensive document collection plan and thereunder reviewed and produced more than 1 million documents relating to a dispute regarding a pharmaceutical commercialization and marketing collaboration agreement between two life sciences companies using a combination of document review and Mintz Levin attorneys.
  • Implemented a litigation hold and document collection protocol for a diagnostic developer and manufacturer with no litigation experience or readiness requiring a comprehensive analysis and identification of more than 30 company employees in Europe and the United States as well as the preservation and collection of more than 2 million pages of documents.
  • On behalf of a diagnostics service provider, successfully negotiated a favorable settlement agreement for a wage and hour class action filed on behalf of pickup and delivery drivers who alleged failure to pay overtime. Majority of the settlement amount was funded by joint defendants based on the client’s position that it was not the principle employer of the putative class members.
  • Represented a biotech company and the company’s directors in two shareholders derivative cases (filed in New Jersey and the Delaware Court of Chancery) alleging breach of fiduciary duty and a federal class action alleging breach of fiduciary duty and violation of Section 14 of the Securities Exchange Act of 1934 arising out of a pending acquisition of the company. Once our client announced the transaction, plaintiffs sued seeking to enjoin the transaction. We opposed the preliminary injunction in Delaware and won at both the trial and appellate levels. We successfully moved to stay the New Jersey state action. The New Jersey federal plaintiff voluntarily dismissed his complaint after receipt of our motion to dismiss papers.
  • Represented a pharmaceutical company in a claim brought by a woman who alleged that she suffered a rare syndrome as a result of her use of an oral contraceptive. A summary judgment issued in the company’s favor by the district court was subsequently affirmed by first circuit in a precedent-setting case regarding scope of “discovery rule” exception to statute of limitations.
  • Represented a pharmaceutical company in wrongful death and personal injury actions involving participants in phase III clinical trials.
  • Serve as national counsel to a large biopharmaceutical company, representing it in many states in cases involving several complex biologic drug products.
  • Currently serve as national e-discovery counsel for a leading biotechnology company building a litigation document database and coordinating discovery efforts in more than 15 state, federal, and international jurisdictions.
  • Successfully defended a life sciences company in a lawsuit brought by a woman who suffered a serious infection allegedly caused by her use of an allegedly contaminated injectable drug, a case involving an unusual manufacturing defect claim.
  • Won a jury verdict defending a global public biotechnology company in a $68 million securities fraud class action suit. In the pretrial phase, Mintz Levin obtained dismissal of the majority of the plaintiffs’ claims. After an eight-day trial, the jury needed just three hours to reach a verdict completely absolving both the company and its chairman of any wrongdoing. The National Law Journal featured the victory as one of the top defense verdicts in the country.
  • Represented a creditors committee and liquidating trustee in the Oscient Pharmaceuticals Corporation Chapter 11 bankruptcy case, including the investigation, litigation, and asset recovery issues.

Real Estate

  • Representation of a major manufacturer in its acquisition of a 90-acre site in Devens, Massachusetts, for the development of a $1.1 billion, state-of-the-art biologic manufacturing facility.
  • Represent Biogen (now Biogen Idec) in connection with its development of a 150,000-square-foot R&D facility and the lease of additional research, development, and office facilities at its Cambridge Center campus.
  • Represent Elan Pharmaceuticals in connection with the purchase, development, and subsequent sale / leaseback of its San Diego headquarters, and its build-to-suit lease and joint venture construction of new facilities totaling over 200,000 square feet in South San Francisco, CA.
  • Represent Millenium Pharmaceuticals, Inc. (now Millennium: The Takeda Oncology Company), in connection with a build-to-suit lease of a 250,000-square-foot R&D and office facility in Cambridge, MA.
  • Represent CareFusion and its affiliates in connection with the purchase and development of corporate headquarters and multiple manufacturing facilities in California, North Carolina, and Mexico.

Tax

  • Assisted the owners of a biotechnology company on the design and implementation of a tax-compliant bonus plan for its key executives in connection with a sale of the company to a strategic buyer and assisted the executives in obtaining the owners’ consent to the payments to avoid the golden parachute excise tax.

Venture Capital & Emerging Companies

  • Represented Intercept Pharmaceuticals, Inc. in its August 2012 $30 million Series C financing led by OrbiMed Advisors and Genextra.
  • Represented AccuVein, Inc. in its July 2012 $7.1 million financing led by MVM Life Sciences Fund, Bessemer Venture Partners, Tullis, and Lynch Foundation.
  • Represented Tarsa Therapeutics, Inc. in its March 2012 $28 million Series B financing led by Foresite Capital, Novo A/S, MVM Life Sciences Fund, and Quaker Partners.
  • Represented Sera Prognostics, Inc. in its November 2011 $19.3 million Series A financing led by Interwest Partners, Domain Partners, Catalyst Health Ventures, Osage University Partners, and UpStart Life Sciences Capital.

Therapeutic

  • Aggamin Pharmaceuticals, LLC
  • AngioChem, Inc.
  • ARIAD Pharmaceuticals, Inc.
  • ArQule, Inc.
  • AVEO Pharmaceuticals, Inc.
  • BeiGene Ltd.
  • Biogen Idec
  • Boston Biomedical, Inc. (acquired by Dainippon Sumitomo Pharma Co., Ltd.)
  • Bristol-Myers Squibb
  • Compugen Ltd.
  • Cureveda, LLC
  • Cyclacel Pharmaceuticals, Inc.
  • Elan Corporation, plc
  • Evotec AG
  • Gamida Cell
  • Hemera Biosciences Inc.
  • ImmunoGen, Inc.
  • Intarcia Therapeutics, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Lotus Tissue Repair, Inc. (acquired by Shire)
  • Mast Therapeutics, Inc.
  • Mimetogen Pharmaceuticals, Inc.
  • Neurimmune Therapeutics AG
  • NovImmune SA
  • OXiGENE, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Prosidion Ltd.
  • Retroscreen Virology
  • SkyePharma PLC
  • Synta Pharmaceuticals Corp.
  • Targacept, Inc.
  • Tarsa Therapeutics, Inc.
  • Teva
  • Veloxis Pharmaceuticals Inc.
  • Vertex Pharmaceuticals Incorporated
  • XenoPort, Inc.

Diagnostic

  • Allegro Diagnostics, Inc.
  • BG Medicine, Inc.
  • Caris Life Sciences, Ltd.
  • Exosome
  • Interleukin Genetics, Inc.
  • Lumicell Surgical, Inc.
  • Miraca Life Sciences, Inc.
  • Myriad Genetics, Inc.
  • Nanobiosym Diagnostics, Inc.
  • Pathway Genomics Corporation
  • Rosetta Genomics Ltd.

Tools & Instrumentation

  • AdvanDx, Inc.
  • Life Technologies Corporation
  • QIAGEN N.V.
  • Roche

Medical Device

  • AccuVein Inc.
  • Adlens Ltd.
  • Alphatec Holdings, Inc.
  • Amedica Corporation
  • Beacon Endoscopic
  • BioHorizons
  • CareFusion Corporation
  • CRISI Medical Systems, Inc.
  • Dräger
  • ForSight Labs
  • GenMark Diagnostics, Inc.
  • GI Dynamics, Inc.
  • Home Dialysis Plus, Inc.
  • iCAD, Inc.
  • Lumos Catheter Systems
  • Medingo
  • NeuroMetrix, Inc.
  • NuVasive, Inc.
  • Pluromed, Inc. (acquired by Sanofi-Aventis)
  • Roche
  • Solx, Inc.
  • Spiracur Inc.
  • Tandem Diabetes Care, Inc.
  • Transcend Medical, Inc.

Upcoming

Past